Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C12H16N2.C2H4O2 |
| Molecular Weight | 248.3208 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)=O.CCC(N)CC1=CNC2=C1C=CC=C2
InChI
InChIKey=TUQLBJAHRWROHB-UHFFFAOYSA-N
InChI=1S/C12H16N2.C2H4O2/c1-2-10(13)7-9-8-14-12-6-4-3-5-11(9)12;1-2(3)4/h3-6,8,10,14H,2,7,13H2,1H3;1H3,(H,3,4)
| Molecular Formula | C2H4O2 |
| Molecular Weight | 60.052 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C12H16N2 |
| Molecular Weight | 188.2688 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
ETRYPTAMINE (MONASE®), similar to the hallucinogenic tryptamines, is an inhibitor of monoamine oxidase, introduced for use as an antidepressant. It was withdrawn from the market due to problems with agranulocytosis and other side effects. However, it's activity is still under scientific investigation.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://patents.google.com/patent/US3296072 https://books.google.ru/books?id=l1DrqgobbcwC&pg=PA102&lpg=PA102&dq=Monase retrieved from Hallucinogens: A Forensic Drug Handbook: Richard R. Laing, Barry L. Beyerstein, Jay A. Siegel, p.102 https://www.ncbi.nlm.nih.gov/pubmed/13685431 https://www.ncbi.nlm.nih.gov/pubmed/13765760 |
Primary | Monase Approved UseDepression Launch Date1960 |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
8.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099943/ |
single, oral |
ETRYPTAMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
50 mg 1 times / day multiple, oral Highest studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 61-93 years Health Status: unhealthy Age Group: 61-93 years Sex: M+F Sources: |
Other AEs: Palpitation, Nervousness... Other AEs: Palpitation (3 patients) Sources: Nervousness (3 patients) |
30 mg 1 times / day multiple, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, 61-93 years Health Status: unhealthy Age Group: 61-93 years Sex: M+F Sources: |
Other AEs: Palpitation, Nervousness... Other AEs: Palpitation (4 patients) Sources: Nervousness (4 patients) |
700 mg single, oral Overdose |
unknown |
Other AEs: Malignant hyperthermia... Other AEs: Malignant hyperthermia (grade 5, 1 patient) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Nervousness | 3 patients | 50 mg 1 times / day multiple, oral Highest studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 61-93 years Health Status: unhealthy Age Group: 61-93 years Sex: M+F Sources: |
| Palpitation | 3 patients | 50 mg 1 times / day multiple, oral Highest studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 61-93 years Health Status: unhealthy Age Group: 61-93 years Sex: M+F Sources: |
| Nervousness | 4 patients | 30 mg 1 times / day multiple, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, 61-93 years Health Status: unhealthy Age Group: 61-93 years Sex: M+F Sources: |
| Palpitation | 4 patients | 30 mg 1 times / day multiple, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, 61-93 years Health Status: unhealthy Age Group: 61-93 years Sex: M+F Sources: |
| Malignant hyperthermia | grade 5, 1 patient | 700 mg single, oral Overdose |
unknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| alpha-Ethyltryptamine (alpha-ET) as a discriminative stimulus in rats. | 2006-10 |
|
| ALPHA-ETHYLTRYPTAMINE (ETRYPTAMINE): AN ELECTROENCEPHALOGRAPHIC, BEHAVIORAL AND NEUROCHEMICAL ANALYSIS. | 1963-07-02 |
|
| The effect of Monase in depressive states: a multi-blind pilot study. | 1961-05 |
|
| Clinical experiences with etryptamine in office practice. | 1961-02 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:24:11 GMT 2025
by
admin
on
Mon Mar 31 18:24:11 GMT 2025
|
| Record UNII |
3RY07R55EE
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C667
Created by
admin on Mon Mar 31 18:24:11 GMT 2025 , Edited by admin on Mon Mar 31 18:24:11 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DBSALT000188
Created by
admin on Mon Mar 31 18:24:11 GMT 2025 , Edited by admin on Mon Mar 31 18:24:11 GMT 2025
|
PRIMARY | |||
|
CHEMBL1619758
Created by
admin on Mon Mar 31 18:24:11 GMT 2025 , Edited by admin on Mon Mar 31 18:24:11 GMT 2025
|
PRIMARY | |||
|
118-68-3
Created by
admin on Mon Mar 31 18:24:11 GMT 2025 , Edited by admin on Mon Mar 31 18:24:11 GMT 2025
|
PRIMARY | |||
|
m727
Created by
admin on Mon Mar 31 18:24:11 GMT 2025 , Edited by admin on Mon Mar 31 18:24:11 GMT 2025
|
PRIMARY | Merck Index | ||
|
204-268-1
Created by
admin on Mon Mar 31 18:24:11 GMT 2025 , Edited by admin on Mon Mar 31 18:24:11 GMT 2025
|
PRIMARY | |||
|
PE 006
Created by
admin on Mon Mar 31 18:24:11 GMT 2025 , Edited by admin on Mon Mar 31 18:24:11 GMT 2025
|
PRIMARY | |||
|
DTXSID2048876
Created by
admin on Mon Mar 31 18:24:11 GMT 2025 , Edited by admin on Mon Mar 31 18:24:11 GMT 2025
|
PRIMARY | |||
|
1083-68-7
Created by
admin on Mon Mar 31 18:24:11 GMT 2025 , Edited by admin on Mon Mar 31 18:24:11 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
8366
Created by
admin on Mon Mar 31 18:24:11 GMT 2025 , Edited by admin on Mon Mar 31 18:24:11 GMT 2025
|
PRIMARY | |||
|
C74236
Created by
admin on Mon Mar 31 18:24:11 GMT 2025 , Edited by admin on Mon Mar 31 18:24:11 GMT 2025
|
PRIMARY | |||
|
300000055486
Created by
admin on Mon Mar 31 18:24:11 GMT 2025 , Edited by admin on Mon Mar 31 18:24:11 GMT 2025
|
PRIMARY | |||
|
3RY07R55EE
Created by
admin on Mon Mar 31 18:24:11 GMT 2025 , Edited by admin on Mon Mar 31 18:24:11 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
PARENT -> SALT/SOLVATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |